Premium
P3‐398: DERIVING AN INFORMED NEUROCOGNITIVE COMPOSITE MEASURE FOR DELAY‐OF‐ONSET TRIALS IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE (MCI‐AD)
Author(s) -
Espeland Mark A.,
Vaughan Leslie,
Romero Heather,
Hayden Kathleen M.,
Plassman Brenda L.,
WelshBohmer Kathleen A.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1492
Subject(s) - dementia , neurocognitive , cognition , verbal fluency test , boston naming test , psychology , audiology , alzheimer's disease , cognitive test , verbal learning , neuropsychology , raw score , cohort , hazard ratio , episodic memory , effects of sleep deprivation on cognitive performance , verbal memory , medicine , disease , psychiatry , confidence interval , statistics , raw data , mathematics
P3-398 DERIVING AN INFORMED NEUROCOGNITIVE COMPOSITE MEASURE FOR DELAY-OF-ONSET TRIALS IN MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (MCI-AD) Mark A. Espeland, Leslie Vaughan, Heather Romero, Kathleen M. Hayden, Brenda L. Plassman, Kathleen A. Welsh-Bohmer, Wake Forest School of Medicine, Winston Salem, North Carolina, United States; Wake Forest University, Winston-Salem, North Carolina, United States; Duke University Medical Center, Bryan ADRC, Durham, North Carolina, United States; Bryan ADRC, Duke University Medical Center, Durham, North Carolina, United States; Duke University, Durham, North Carolina, United States; Duke University-Bryan ADRC, Durham, North Carolina, United States. Contact e-mail: mespelan@wakehealth.edu